Thrombotic microangiopathic
Thrombotic thrombocytopenic purpura
A disorder characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurological abnormalities such as seizures, hemiplegia, and visual disturbances. It is an acute or subacute condition.
A kind of blood disorder that causes blood clots to form in blood vessels around the body
An acquired, congenital, or familial disorder caused by platelet aggregation with thrombosis in terminal arterioles and capillaries. Clinical features include thrombocytopenia; hemolytic anemia; azotemia; fever; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as renal failure.
An acute or subacute syndrome characterized by the presence of microangiopathic hemolytic anemia, thrombocytopenic purpura, fever, renal abnormalities and neurologic abnormalities such as seizures, hemiplegia, and visual disturbances. Drugs and bacteria have been implicated as etiologic factors. The introduction of plasma exchange has significantly lowered the mortality rate. If untreated, the mortality rate is high.
Diseases that result in thrombosis in microvasculature. The two most prominent diseases are purpura, thrombotic thrombocytopenic; and hemolytic-uremic syndrome. Multiple etiological factors include vascular endothelial cell damage due to shiga toxin; factor h deficiency; and aberrant von willebrand factor formation.
The syndromes of microangiopathic hemolytic anemia, thrombocytopenia, and variable signs of organ impairment, due to platelet aggregation in the microcirculation.
M31.1 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
The 2023 edition of ICD-10-CM M31.1 became effective on October 1, 2022.
This is the American ICD-10-CM version of M31.1 – other international versions of ICD-10 M31.1 may differ.